glucametacin and Rheumatic-Diseases

A double blind clinical study has been carried out with two non-steroid anti-inflammatory drugs, glucametacine and phenylbutazone in 40 patients suffering from inflammatory and degenerative type arthrorheumopathies, selected and randomised into two groups. Examination of results shows the greater effectiveness of glucametacine (78%)over phenylbutazone (60%). Glucametacine was also statistically (p < 0,05) better from the tolerance point of view.

Topics: Adult; Aged; Anti-Inflammatory Agents; Bone Diseases; Clinical Trials as Topic; Female; Glucosamine; Humans; Indomethacin; Joint Diseases; Male; Middle Aged; Rheumatic Diseases

Teorema and indometacin were administered to patients with degenerative and inflammatory joint diseases and degenerative vertebral column diseases for a period of 21 days. 24 patients were included in the 3 groups distinguished by diagnostic criteria. The daily Teorema dose was 420 mg in 21 cases and 210 mg in 3 cases; that of indometacin was 150 mg in 22 cases and 75 mg in 2 cases. Both drugs were given orally as capsules (25 mg indometacin/capsule and 70 mg Teorema/capsule). Both compounds produced a highly significant improvement of symptoms. Laboratory tests at regular intervals failed to reveal any substantial deviations from normal in both treatment groups. In conclusion, the results of the double blind trial suggest that Teorema, a new anti-inflammatory substance, when administered at a dose of approximately 420 mg/day, produces a beneficial effect in many rheumatoid conditions, while causing remarkably few side effects.

Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Glucosamine; Humans; Indomethacin; Male; Middle Aged; Rheumatic Diseases

Twenty-three patients with rheumatoid arthritis and 9 patients with other forms of rheumatic diseases were treated for 20 days with 420 mg glucametacin per day, given as three 140 mg capsules. The treatment produced anti-inflammatory effects which were rated as good in about half the cases, with improvement of the majority of the clinical parameters studied. There were mild digestive side-effects. One patient with gallstones developed biliary colic, but the relationship of this to glucametacin treatment was not clear. The results obtained in the 32 patients treated with 140 mg glucametacin capsules were very similar to those which the same authors had observed in a very extensive case series of patients with rheumatic diseases treated with the same daily dose, but given as 70 mg capsules. It is suggested that the new preparation, which halves the number of capsules taken each day, is to be preferred to the smaller dose capsules.

Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Capsules; Chronic Disease; Female; Glucosamine; Humans; Indomethacin; Inflammation; Male; Middle Aged; Rheumatic Diseases

Topics: Aged; Anti-Inflammatory Agents; Female; Geriatrics; Glucosamine; Humans; Indoleacetic Acids; Indomethacin; Joint Diseases; Male; Middle Aged; Rheumatic Diseases; Spinal Diseases